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Abstract: Survival data analysis results are usually communicated through the overall survival 
probability. Alternative measures provide additional insights and may help in communicating 
the results to a wider audience. We describe these alternative measures in two data settings, 
the overall survival setting and the relative survival setting, the latter corresponding to the 
particular competing risk setting in which the cause of death is unavailable or unreliable. In the 
overall survival setting, we describe the overall survival probability, the conditional survival 
probability and the restricted mean survival time (restricted to a prespecified time window). 
In the relative survival setting, we describe the net survival probability, the conditional net 
survival probability, the restricted mean net survival time, the crude probability of death due 
to each cause and the number of life years lost due to each cause over a prespecified time 
window. These measures describe survival data either on a probability scale or on a timescale. 
The clinical or population health purpose of each measure is detailed, and their advantages 
and drawbacks are discussed. We then illustrate their use analyzing England population-based 
registry data of men 15–80 years old diagnosed with colon cancer in 2001–2003, aiming to 
describe the deprivation disparities in survival. We believe that both the provision of a detailed 
example of the interpretation of each measure and the software implementation will help in 
generalizing their use.
Keywords: survival, competing risks, relative survival setting, conditional survival, restricted 
mean survival time, net survival, crude probability of death, number of life years lost
Introduction
In epidemiology, survival data are commonly described with the probability of being 
alive after a certain time after the diagnosis of a particular disease. However, depending 
on the objectives, i) evaluating the patients prognosis or ii) giving useful information 
for public health policy, alternative measures may be useful. For both objectives, data 
gathered by population-based registries are one of the main sources of information 
because they represent the whole population.1 Additionally, many diseases are more 
prevalent among older groups of the population, who are also more likely to experi-
ence competing risks of death. Thus, one additional complexity is to disentangle the 
impact on survival of the disease under study from other causes of death. Because 
the cause of death is not routinely collected in population-based registries, or may be 
inaccurate or unreliable, especially for long-term studies as it may be diversely coded 
over time and on different regions,2–5 specific methods have been developed to allow 
the estimation of quantities associated with the disease under study without the need for 
the cause of death, known as the “relative survival” setting. These methods have been 
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mainly used in cancer epidemiology, with some attempts in 
other clinical areas (explained in the “Discussion” section).
Our aim is to provide an overview of different time-
to-event measures that can be used to summarize survival 
data in both the overall survival setting and the “relative 
survival” setting and to introduce them in a way they can 
be interpreted and estimated by applied researchers. In the 
overall survival setting, these measures are the overall sur-
vival, the conditional survival (CS) and the restricted mean 
survival time (RMST). In the “relative survival” setting, the 
measures detailed below are the net survival (NS), the con-
ditional net survival (CNS), the restricted mean net survival 
time (RMNST), the crude probabilities of death (CPD) due 
to each competing cause and the number of life years lost 
(NLYL) due to each competing cause. We illustrate their 
use and interpretation using a cancer epidemiology example 
with public health policy implications, where we display 
survival socioeconomic disparities after the diagnosis of 
colon cancer. We discuss their usefulness distinguishing 
clinical perspective from population health perspective. For 
reproducibility, we also provide R code for the derivation 
and the computation of all the measures introduced in the 
Supplementary materials.
Theoretical framework
Consider a group of patients diagnosed with a specific type 
of cancer and followed up over a period of time. During this 
period, we observe the time to death T
i
 for a patient i, with 
the corresponding vital status d
i 
= 1 (death). Patients lost to 
follow-up or alive at the end of the observation period are 
censored (d
i 
= 0) at the time of their last known vital status. 
Additionally, some prognosis variables X
i
, such as gender, 
age, among others, are known.
We consider two different settings, namely, the overall 
survival setting and the relative survival setting. The overall 
survival setting is the classical choice for survival data analy-
sis, where the only information used in the analysis are T
i
 
and d
i
, for patient i, among some patient-level characteristics. 
In the relative survival setting, we account for the fact that 
patients may die from other causes than cancer and our inter-
est translates to the survival experience related to a specific 
cause of interest. However, when analyzing population-based 
data, the cause of death is missing or not reliably known, thus 
leading to the relative survival setting. The relative survival 
setting is based on competing risks theory but applied to 
population-based data where the cause of death is unavailable. 
This distinction is useful because some statistical measures 
are defined only in the relative survival setting. In this set-
ting, we use the expected or population mortality hazard as 
additional information in order to derive quantities specifi-
cally associated to the cancer under study.
the “classical” overall survival setting
overall survival and conditional survival probabilities
The survival probability P(T>t) quantifies the probability to 
be alive after a certain time point t, and it can be written in 
terms of the mortality hazard l(t) through the relationship 
S t u du
t
( ) = − ( )∫exp( )
0
l . It follows that 1-S(t) quantifies the 
(cumulative) probability of death before time t, P(T ≤ t). An 
additional quantity that can be easily derived is the CS,6–10 
CS(t|s), defined as the probability of surviving further “t” 
years given that a patient has already survived “s” years 
after the diagnosis:7
CS t s P T t s T s
S s t
S s
u du
s
s t
| ( | exp( ) = > + > = +( )( ) = − ( )
+∫) ( )l  (1)
It gives an updated survival probability for patients who 
survived up to time “s” and reflects the impact of late effects, 
complications or occurrence of late events (eg, recurrences) 
as their mortality hazard varies over time. This measure can 
be used as a function of the time point s, at which the predic-
tion is made in order to obtain the probability that a patient 
survives at least “t” more years7 after surviving the first “s” 
years from diagnosis. It could be useful to compare patient’s 
prognosis after say 1 year of follow-up, as the mortality 
hazard is often high during the first year after diagnosis, 
hence the cohort of patients surviving the first year may have 
different characteristics compared to the original cohort of 
patients. This measure is also related to the probability of 
the remaining life (also known as probability of the residual 
life), which is defined as PRL t s P T t s T s| ( |( ) = ≤ + > ) . The 
probability of the remaining life (PRL) is the probability that 
patients die within “t” years after having already survived 
“s” years from diagnosis.11
Restricted mean survival time
The mean survival time (MST) is the expected period of time 
that patients will survive after their cancer diagnosis. The 
calculation of the MST requires the estimation of the entire 
survival function (that is, until to the point when the survival 
probability reaches 0, in other words the follow-up is long 
enough for all events to be observed). This is an important 
limitation in practice given that survival data are typically 
right-censored due to random dropout or limited follow-up. 
This implies that the right-hand tail of the survival function 
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is usually unobserved (ie, we do not observe the deaths for 
the whole cohort). The RMST represents an alternative mea-
sure that overcomes this limitation12–17 and is defined as the 
mean survival time over a prespecified time window [0-τ]. 
The RMST is interpreted as the τ-year life expectancy. In 
mathematical terms, the RMST(τ) is defined as
RMST S u dut
t
( ) = ( )∫
0
   (2)
It can be seen from the previous equation that the RMST 
is simply the area under the survival curve between time 0 and 
τ (Figure 1). This measure is defined on the timescale (instead 
of the probability scale) and is therefore quite attractive due 
to its simplicity for both interpretation and communication 
in clinical setting.14,16,18 Moreover, the RMST is an appealing 
outcome measure as it produces a single summary value even 
in cases when the hazard ratio varies with time since diagno-
sis (ie, nonproportional hazards).14,19 Therefore, quantifying 
a difference between treatments using the RMST provides 
a clinically meaningful measure, compared to an estimated 
hazard ratio, only relevant in the limited number of scenarios 
where the proportional hazards assumption is reasonable.
Notice the reversed perspective with the restricted mean 
time lost (RMTL),16
 
RMTL S u du S u dut t
t t
( ) = − ( ) = − ( )∫ ∫
0 0
1 ,
 
which is interpreted as the expected number of years lost before 
time τ (compared to an “immortal” cohort). Geometrically, 
this quantity is the area above the survival curve (Figure 1).
Accounting for competing risks in the 
relative survival data setting
Net survival
Cancer patients may die from causes other than the cancer under 
study. However, in the relative survival setting, the cause of 
death is not available (or unreliable) and the mortality hazards 
from other causes are provided by the background mortality 
from the general population to deduce the excess mortality 
hazard that can be attributed, directly or indirectly, to the cancer 
under study. In mathematical terms, this means that the overall 
mortality hazard lOi, for patient i, is the sum of two hazards, the 
excess hazard lEi (associated to the cancer under study) and the 
expected hazard l
Pi
(coming from the general population):20–25
l l lOi Ei Pit t t( ) = ( ) + ( )    (3)
The expected mortality hazard l
Pi is assumed to be 
known. In practice, l
Pi
 is usually obtained from life tables 
built by national statistics institutes and stratified on some 
sociodemographic variables (such as age, sex, calendar year, 
deprivation and region).
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RMST(τ=10)=5.45 years
NLYLcancer(τ=10)=2.92 years
NLYLother(τ=10)=1.63 years
3.4
S(t=3.4)=0.64
CPDother(t=3.4)=0.13
CPDcancer(t=3.4)=0.23
Figure 1 graphical representation of the different measures using simulated data: the overall survival probability (dashed black curve), the 10-year RMSt (lower shaded 
area), the Nlyl at 10 years according to each cause (Nlylcancer – upper shaded area and Nlylother – middle shaded area, which sum up to give the RMtl), and the curves of 
the CPd due to cancer (CPdcancer) and due to other causes (CPdother), using a (reverse) stacked display format.
Note: Simulated data were used for this graphical representation; therefore, the values do not match the estimated values from the manuscript (which were based on real 
data).
Abbreviations: CPd, crude probability of death; Nlyl, number of life years lost; RMSt, restricted mean survival time; RMtl, restricted mean time lost.
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The hazard functions in equation (3) are defined at “indi-
vidual level”. From this hazard structure in equation (3), we 
can derive marginal hazard and marginal survival functions 
(ie, defined at the “population level”). The NS function of 
a patient i is the survival derived from the excess mortality 
hazard S t u duNi
t
Ei( ) = − ( )∫exp( )
0
l , while the NS of the 
whole cohort (ie, marginal) is the average of individual NS 
functions: S t
n
S tN
i
n
Ni( ) = ( )
=
∑1
1
. NS does not depend on 
mortality from other causes,22,23,26 so it is most useful for 
comparing different populations after age standardization 
to account for the difference in the structure of age between 
populations.27,28 It estimates the survival that cancer patients 
would experience if they could only die from the cancer under 
study. A nonparametric estimator of NS, relying on counting 
process theory, was proposed by Perme et al.23 This estimator 
is based on estimating the cumulative excess hazard in order 
to deduce the NS of the whole cohort S
N
(t). The marginal net 
hazard (ie, defined for the whole cohort) is derived from the 
marginal NS as a weighted sum of the individuals’ excess 
hazards (Supplementary materials for more explanations on 
the formulas):
l lN
i
n
Ni
i
n
Ni
Eit
S t
S t
t( ) = ( )
( )
( )
=
=
∑∑1 1
  (4)
It is worth noting that the link between individual and 
marginal hazards to account for individuals’ heterogeneity also 
exists in the overall survival setting (Supplementary materi-
als), but is less important to be presented compared to the 
relative survival setting, as explained later in the manuscript 
(explained in the “Crude probability of death (CPD)” section).
Conditional net survival probability
Analogous to the overall survival setting, the CNS, CNS (t|s) 
is the probability patients survive further “t” years given that 
they have already survived “s” years after the diagnosis, but 
in the hypothetical situation where they could only die from 
the cancer under study:29–32
CNS t s
S s t
S s
N
N
|( ) = +( )( )   (5)
Restricted mean net survival time (RMNSt)
Analogous to the derivation of the RMST in the overall 
survival setting (equation 2), the RMNST is defined in the 
relative survival setting as
RMNST S u duNt
t
( ) = ( )∫
0
  (6)
with the NS function replacing the overall survival from 
equation (2).
The RMNST represents the mean NS over a prespecified 
time window [0,τ] and quantifies the mean time patients 
would survive if they were only exposed to the mortality 
hazard due to cancer between 0 and τ years from the diag-
nosis. Given that this measure is not affected by other causes 
of death, it represents a useful tool for comparing different 
populations. In addition, this measure can be derived with any 
NS model, including nonproportional excess hazard models, 
in contrast to other comparison tools such as log-rank-based 
test for comparing NS curves which loses power in case of 
nonproportional hazards.33,34
Crude probability of death (CPd)
For this measure, we first need to define the marginal cause-
specific hazard l
C
(t) and the marginal expected mortality 
hazard l
P
(t) (ie, defined on the whole population, Supple-
mentary materials). They are also derived from Equation 3:
l lC
i
n
i
i
n
i
Eit
S t
S t
t( ) = ( )
( )
( )
=
=
∑∑1 1   (7)
l lP
i
n
i
i
n
i
Pit
S t
S t
t( ) = ( )
( )
( )
=
=
∑∑1 1
  (8)
At this point, it is crucial to highlight the difference 
between the marginal net hazard l
N
(t) and the marginal 
cause-specific hazard l
C
(t). Both are based on a weighted 
average of individuals’ excess hazards,23 and the differ-
ence lies in the weights that multiply the individual excess 
hazards, which are either based on the individual’s NS, 
S t u duNi
t
Ei( ) = − ( )



∫exp 0l  or on the individual’s over-
all survival S t u dui
t
Oi( ) = − ( )



∫exp 0l  (Supplementary 
materials). In other words, l
N
(t) does not depend on the 
individuals’ expected mortality hazards, while l
C
(t) does. 
Notice that if the individual excess hazards are identical 
for all patients (ie, no heterogeneity observed between 
patients), then the two population hazards l
N
(t) and l
C
(t) 
are equal.23
The CPD due to cancer F
C
(t) and the CPD due to other 
causes F
P
(t) are defined as
F t S u u duC
t
C( ) = ( ) ( )∫
0
l   (9)
F t S u u duP
t
P( ) = ( ) ( )∫
0
l   (10)
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The function F
C
(t) represents the probability of dying 
from cancer under study before time t, in the presence of 
other causes of death. F
P
(t) represents the probability of dying 
from other causes before time t, in the presence of cancer 
as a cause of death.35,36 More specifically, by splitting the 
overall mortality hazard of a group of individuals as the sum 
of the cause-specific mortality hazard and the other-cause 
mortality hazard, the probability of death can be written as 
the sum of the probability of death due to cancer and that 
due to other causes (Figure 1; Supplementary materials). 
The crude probability F
C
(t) is an indicator relevant to cancer 
patients interested in their prognosis as well as for health care 
planning.24,35,37–39 In the classical competing risks framework 
(ie, with known and reliable information on cause of death), 
this measure is also known as the cause-specific cumulative 
incidence function40,41 or the absolute cause-specific risk of 
death.42
Number of life years lost (Nlyl)
The restricted mean of time lost can be decomposed accord-
ing to the cause of death.43 This decomposition can be 
extended to the relative survival setting. Since the overall 
probability of death is equal to the sum of the probability of 
death from cancer and the probability of death from other 
causes, 1− ( ) = ( ) + ( )S t F t F tP C , we integrate this function 
between 0 and τ and decompose the RMTL(τ) (Figure 1) as
RMTL S t dt F t dt F t dtP Ct
t t t
( ) = − ( )( ) = ( ) + ( )∫ ∫ ∫
0 0 0
1   (11)
where each term on the right-hand side of the equation cor-
responds to the mean NLYL due to population mortality 
and cancer-specific mortality over a t-year time window, 
respectively.35
NLYL F t dtP Pt
t
( ) = ( )∫
0
  (12)
NLYL F t dtC Ct
t
( ) = ( )∫
0
  (13)
We can also use this decomposition to compare the cancer 
patients to the general population, in order to quantify how 
many years of life expectancy patients lose because of the 
cancer.43–45 Rearranging Equation 11, the NLYL due to the 
cancer before time τ, NLYL
C
(τ), is defined as
NLYL F t dt F t dt S t dtC C Pt
t t t
( ) = ( ) = − ( ){ } − ( )∫ ∫ ∫
0 0 0
1   (14)
where the quantity 1-F
P
(t) can be replaced by S
P
(t), ie, the 
classical survival function using the population mortality 
rates l
P
. Equation 14 shows that the NLYL due to the can-
cer before time τ is simply the difference between the area 
under the curve of the population survival minus the area 
under the curve of the overall survival (ie, the area between 
the two curves).46,47
Estimation
In both settings (overall and relative survival) and for each 
measure summarized in Table 1, we followed the same prin-
ciple of estimation; we used nonparametric estimators and 
plugged them in the corresponding formulas. In the overall 
survival setting, we used the nonparametric Kaplan–Meier 
estimator40,48 for overall survival and CS probabilities and for 
RMST(τ). In the relative survival setting, we used the nonpara-
metric Pohar-Perme estimator23 of NS, CNS and  RMNST(τ). 
For the CPD and the NLYL, we used an Aalen–Johansen type 
estimator defined in the relative survival setting. All analyses 
were done with the R software (R Foundation for Statistical 
Computing, Vienna, Austria), version 3.2.4 and the packages 
survival and relsurv. For the standard errors of the estimates, 
we used analytical formulas when available, or we used non-
parametric boostrap49 using the R-package boot (for the CNS 
and the RMNST). Supplementary materials detail the R code 
to perform the estimations.
Material for the illustration
To illustrate the usefulness and the interpretations of the 
different measures, we analyzed records of males diagnosed 
with colon cancer, obtained from the England population-
based cancer registry. We aimed to describe socioeconomic 
disparities in (cancer) survival. We limited the analysis to 
the patients diagnosed between 2001 and 2003 and aged 
between 15 and 80 years old at diagnosis and followed up 
up to December 31, 2014. Thus, all patients had a minimum 
potential follow-up of 10 years. Estimation in the relative 
survival setting used life tables stratified by age, sex, calendar 
year, Government office region and deprivation.
Patients were categorized in five socioeconomic status 
groups (from the least deprived group, level 1, to the most 
deprived group, level 5) using national quintiles of the income 
domain score of the Index of Multiple Deprivation (IMD 
2004),50 which is a score defined at the lower super output area 
level in England (geographical area of approximately 1,500 
inhabitants). The income domain score combines five indica-
tors, and it measures the proportion of the population in an area 
experiencing deprivation related to low income. When mea-
sured at a relatively small geographical level, this ecological 
deprivation score is considered as a good proxy of individual 
deprivation, while additionally measuring the patients’ social 
and economic environment.51,52 Methodological guidelines 
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describe the use of such ecological deprivation scores in the 
context of cancer survival and discuss their limits.53
Ethics approval
We obtained the ethical and statutory approvals required 
for this research (PIAG 1-05(c)/2007; ECC 1-05(a)/2010; 
ethical approval updated April 6, 2017 (REC 13/LO/0610)), 
from the Confidentiality Advisory Group (CAG) part of the 
Health Research Authority (HRA). 
Results
A total of 14,316 deaths out of 19,853 patients occurred over 
the study period. The group aged between 65 and 74 years 
constituted over 40% of the patients under study (Table 2).
overall survival setting
Survival and CS probabilities
The 10-year overall survival probability for all ages com-
bined was 0.36 (95% confidence interval [CI]: 0.34, 0.37) 
for deprivation group 1, and 0.25 (95% CI: 0.24, 0.27) for 
deprivation group 5 (Table 3), and the 10-year overall survival 
probabilities by deprivation and age group are detailed in 
Table S1 and Figure S1.
The CS gives a more optimistic picture of the prognosis, 
even though the deprivation disparities remain substantial: 
once patients survived the first 5 years, the probability to sur-
vive 5 more years CS(5|5) was 0.76 (95% CI: 0.74, 0.78) for 
the least deprived and 0.68 (95% CI: 0.66, 0.71) for the most 
deprived (Table 3). The deprivation disparity was observed 
in all age groups (Table S2; Figure S2).
RMSt
We estimated the 10-year RMST by deprivation group, for 
all ages combined (Table 3) and by age group (Table S3; 
 Figure S3). The RMST at 10 years was estimated as 
5.14 years, (95% CI: 5.01, 5.27) for the least deprived group 
compared to 4.16 years (95% CI: 4.03, 4.30) for the most 
deprived group of patients (Table 3).
While the 10-year RMSTs were almost similar across 
deprivation categories in the group aged 15–44 years, they 
differ by more than 1 year in the age groups 55–64 and 
65–74 years. Patients aged 55–64 years survived on average 
5.76 years (95% CI: 5.5, 6.02) in the least deprived group 
vs 4.73 years (95% CI: 4.43, 5.03) in the most deprived 
group of patients (Table S3). Patients aged 65–74 years 
survived on average 5.15 years (95% CI: 4.95, 5.34) in the 
least deprived group vs 4.04 years (95% CI: 3.83, 4.24) in 
the most deprived group.T
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Relative survival setting
NS and CNS probabilities
The 10-year NS still displays a clear disparity by depriva-
tion group even though slightly reduced compared to the 
overall survival (Table 4). These disparities of NS between 
deprivation groups remained by age group (Table S4; Figure 
S4). However, the deprivation disparity almost disappear 
on the CNS(5|5) for all ages combined (Table 4), and also 
by age group for patients younger than 74 years (Table S5; 
Figure S5). A nice illustration is given by cancer patients 
aged 55–64 years: the CNS(5|1) is quite different between 
the most deprived group and the other groups. But as the 
time we are conditioning on passes, the difference narrows 
(Table S5; Figure S5). It shows that most of the difference 
between deprivation groups happened during the beginning 
of the follow-up, while after 5 years, the excess mortality 
hazard was almost the same in the different deprivation 
groups, except for the group of age 75–80 years.
RMNSt
The RMNST at 10 years quantifies the average time patients 
would survive if they were only exposed to cancer-specific 
mortality during the next 10 years. Between the least and 
most deprived groups, a difference of 0.7 years was estimated: 
5.74 years (95% CI: 5.58, 5.90) vs 5.02 years (95% CI: 4.84, 
5.19) (Table 4). Differences in RMNST at 10 years were 
observed across all age groups; RMNST decreases while 
deprivation increases, with a steeper decrease for the most 
deprived group (Table S6; Figure S6).
CPd
The CPD gives an overall picture of the patients’ prognosis. 
All ages combined, the CPD from cancer 10 years after diag-
nosis was estimated as 0.50 (95% CI: 0.49, 0.52) for the least 
deprived and 0.56 (95% CI: 0.54, 0.58) for the most deprived 
(Table 4), while the CPD from other causes at 10 years was 
0.14 (95% CI: 0.13, 0.14) for deprivation group 1 and 0.19 
(95% CI: 0.19, 0.20) for deprivation group 5. We contrasted 
graphically the prognosis of death from cancer and from 
other causes, between the least deprived group and the most 
deprived group (Figure S7). By age group, the differences 
between the least and the most deprived groups were more 
pronounced for patients aged 55–64 and 65–74 years, with 
substantial differences in both CPD from cancer and from 
other causes (Table S7).
Nlyl
Disparities of survival between deprivation groups could also 
be quantified using the NLYL due to cancer and other causes. 
For the most deprived, the NLYL at 10 years due to cancer 
was 4.14 years (95% CI: 3.97, 4.28) and was 0.72 years 
(95% CI: 0.70, 0.75) due to other causes, compared to 4.77 
(95% CI: 4.60, 4.94) and 1.08 (95% CI: 1.03; 1.12) in the 
least deprived group, respectively (Table 3). Those disparities 
varied by age group. In the 55–64 years age group, the NLYL 
due to cancer was around 4 years for deprivation groups 1–4, 
Table 2 Number of cases (K) and deaths (d) observed before 
december 31, 2014, in men aged between 15 and 80 years old 
at diagnosis and diagnosed between 2001 and 2003 in England, 
by deprivation and age at diagnosis groups (deprivation 1 
corresponding to the less deprived and 5 to the most deprived)
Age at 
diagnosis
Deprivation group Total
1 2 3 4 5
[15;44] K 122 116 118 123 128 607
d 57 55 59 57 72 300
[45;54] K 326 322 294 287 275 1,504
d 169 181 156 177 163 846
[55;64] K 1,017 978 898 911 756 4,560
d 589 583 544 577 531 2,824
[65;74] K 1,699 1,740 1,680 1,669 1,482 8,270
d 1,180 1,248 1,200 1,247 1,200 6,075
[75;80] K 905 1,038 1,052 1,080 837 4,912
d 766 902 887 944 772 4,271
Total K 4,069 4,194 4,042 4,070 3,478 19,853
d 2,761 2,969 2,846 3,002 2,738 14,316
Table 3 Measures estimated in the classical survival setting, in men aged between 15 and 80 years old at diagnosis by deprivation group 
(dep), with their 95% CIs: the survival probability at 10 years after diagnosis S(t=10), the conditional probability of surviving further 
t=5 years given that a patient already survived s = 5 years CS(t=5|s=5), and the restricted mean survival time at 10 years RMST(τ = 10)
Dep 1 Dep 2 Dep 3 Dep 4 Dep 5
S (t=10) (%) 0.36 (0.34–0.37) 0.33 (0.32–0.35) 0.34 (0.32–0.35) 0.30 (0.28–0.31) 0.25 (0.24–0.27)
CS(t=5|s=5) (%) 0.76 (0.74–0.78) 0.74 (0.72–0.76) 0.75 (0.73–0.77) 0.73 (0.70–0.75) 0.68 (0.66–0.71)
RMST(τ = 10) 5.14 (5.01–5.27) 4.93 (4.80–5.05) 4.92 (4.79–5.05) 4.58 (4.45–4.70) 4.16 (4.03–4.30)
Abbreviations: CS, conditional survival; RMSt, restricted mean survival time.
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and it was more than 4.5 years for the most deprived. The 
disparities in NLYL due to other causes were also substantial 
in age groups 55–64 and 65–74 years (Table S8; Figure S8).
Discussion
Survival data are typically summarized through the prob-
ability of being alive after a certain amount of time. Even 
though this probability is a measure which cannot be directly 
assigned to individual patients (because of many unknown 
prognostic factors), it represents the main indicator patients 
(and their clinicians) are interested in. Nevertheless, alter-
native measures can be useful as they provide additional 
insights into the data as well as alternative ways of com-
municating cancer prognostic information to different 
target audiences. This need for presenting cancer survival 
statistics in different and complementary ways to patients, 
clinicians and policy makers becomes even more relevant as 
the burden of cancer rises worldwide.39 Using colon cancer 
data of men diagnosed in England between 2001 and 2003 
and followed up for 10 years, we illustrated the use of these 
alternative measures (Table 1). Overall survival shows clear 
deprivation-related pattern, and even after conditioning on 
being alive at 5 years after diagnosis, the probability to be 
alive after 5 more years still displays deprivation disparities 
(CS). The same is observed with the RMST, while quanti-
fied on a timescale. However, those measures are not able 
to separate the deprivation disparities associated to cancer-
specific mortality from that due to other causes. Accounting 
for the differences in expected mortality between deprivation 
groups is feasible using the relative survival setting (and its 
associated methodology); the obtained results in our example, 
however, do not explain much of these disparities. This 
methodology also allows to provide absolute risk of death for 
patients according to the cause of death, namely, cancer and 
other causes. Those absolute risks can be translated on the 
timescale using the NLYLs. It is however important to bear in 
mind that, when interest lies in comparing two populations, 
the use of NS methods (and other related measures such as 
CNS or RMNST) does not prevent to use conventional age 
standardization to account for differences in the age structure 
of the population.
We propose to (broadly) classify these alternative mea-
sures into two groups: those with a clinical perspective 
(for patients and clinicians) and those with a population 
health perspective (for health policy makers and economic 
evaluations).
From a clinical perspective, the CS is a measure providing 
an updated picture of the prognosis and thus a more hopeful 
value to communicate to patients, along their cancer path-
way.7 Moreover, the CS could easily be extended to different 
scenarios, such as the recurrence-free survival.54 When inter-
est lies in detailing the prognosis according to the cause of 
death, the crude probabilities of death complement the overall 
survival, as it distinguishes death from cancer to death from 
other causes. The CPD is a useful measure of the absolute risk 
of death for cancer patients and has been shown to improve 
patient’s understanding of survival statistics.55 Still within 
a clinical perspective, intuitive and “easy to communicate” 
measures are those based on a metric of time (instead of prob-
ability), such as the RMST over a τ-year period of time and 
Table 4 Measures estimated in the relative survival setting, in men aged between 15 and 80 years old at diagnosis by deprivation group 
(dep), with their 95% CIs: the NS probability at 10 years after diagnosis  NS(t = 10), the CNS,  CNS(t = 5|s = 5), the RMNSt at 10 years 
RMNST (τ = 10), the crude probability of death at 10 years for cancer FC(t = 10) and other causes FP(t = 10) , and the number of life 
years lost due to cancer NLYLC(τ = 10) and due to other causes NLYLP(τ = 10) over a 10-year time window
Dep 1
Estimate (95% CI)
Dep 2
Estimate (95% CI)
Dep 3
Estimate (95% CI)
Dep 4
Estimate (95% CI)
Dep 5
Estimate (95% CI)
NS (t = 10) (%) 0.47 (0.45–0.49) 0.46 (0.44–0.48) 0.50 (0.48–0.52) 0.46 (0.44–0.49) 0.40 (0.38–0.43)
CNS (t = 5|s = 5) (%) 0.89 (0.87–0.92) 0.90 (0.87–0.92) 0.94 (0.91–0.97) 0.93 (0.90–0.96) 0.88 (0.84–0.92)
RMNST (τ = 10) 5.74 (5.58–5.90) 5.61 (5.45–5.76) 5.76 (5.57–5.92) 5.43 (5.29–5.59) 5.02 (4.84–5.19)
Crude probability of death
FC (t = 10) 0.50 (0.49–0.52) 0.51 (0.49–0.53) 0.48 (0.46–0.50) 0.51 (0.49–0.53) 0.56 (0.54–0.58)
FP (t = 10) 0.14 (0.13–0.14) 0.16 (0.15–0.16) 0.19 (0.18–0.19) 0.19 (0.18–0.19) 0.19 (0.19–0.20)
Number of life years lost
NLYLC (τ = 10) 4.14 (3.97–4.28) 4.24 (4.09–4.38) 4.11 (3.95–4.26) 4.4 (4.24–4.55) 4.77 (4.60–4.94)
NLYLP (τ = 10) 0.72 (0.70–0.75) 0.83 (0.80–0.86) 0.97 (0.94–1.01) 1.03 (0.99–1.06) 1.08 (1.03–1.12)
Abbreviations: CNS, conditional net survival; Nlyl, number of life years lost; NS, net survival; RMNSt, restricted mean net survival time.
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the NLYL due to each cause. Those metrics help to quantify 
the loss in life expectancy (within a predefined time frame) 
between different groups.
From a population health perspective, the measures based 
on the net survival (NS, CNS and RMNST) are useful for 
comparison purposes. They allow comparisons of different 
populations, within a country (different periods or subpopu-
lations) or between countries (for example, to compare the 
performance of their health care system in managing cancer 
patients). Those comparisons are not affected by the differ-
ences in background mortality between populations. The NS 
quantifies the differences on a probability scale, the RMNST 
on a timescale, while the CNS gives an updated picture of the 
NS over time since diagnosis. A way of deriving a CI for the 
difference between (say) the NS in deprivation group 1 and 
the NS in deprivation group 5 could be the use of resampling 
methods, such as nonparametric bootstrap. One should, how-
ever, notice that this corresponds to a single time point dif-
ference, while testing difference between deprivation groups 
of the NS curves would be more of interest.33,34 Comparing 
RMNST curves would be an interesting extension of a work 
already done for the RMST,17 where the authors proposed a 
more sophisticated method for deriving simultaneous CIs. 
Other authors derived statistical tests and procedures when 
comparing the RMST in the context of clinical trials.56,57 
Measures based on NS are defined in a hypothetical world 
where patients could only die from their disease. Thus, their 
usefulness is mostly for comparisons in population health 
perspectives, but not for patient’s actual prognosis. If one 
is interested in quantifying how a given variable affects the 
cancer-specific mortality hazard (etiological assessment), the 
excess mortality hazard is the quantity to use,25,58–60 which is 
in line with the recommendation usually made in the classi-
cal competing risks setting when comparing cause-specific 
hazards instead of cumulative incidence functions.41,61 The 
excess mortality hazard helps to assess the cancer prognosis 
for patients, ie, the lethality of the cancer.
The perspective of the health economist is more, for 
example, in quantifying the burden of a given disease on the 
society and how that disease affects the population, possibly 
during their working life. In that sense, the NLYL might be 
of interest to quantify the economic cost of patients’ years of 
life lost at working age because of the disease. Health policy 
makers may use NLYL to quantify, for instance, the number 
of life years that could be saved by allocating more resources 
or reforming/changing the health care system.
We illustrated the use of these measures in cancer epide-
miology, but they could also be used in other clinical areas, 
where the assumption that patients can only die from the 
disease under study is still reasonable, such as survival after 
a HIV infection or following a stroke or a kidney disease 
diagnosis. Applying the CS and the RMST in those clinical 
areas can be done as detailed in the previous sections. For 
the relative survival setting, some research has already been 
done to estimate the excess mortality hazard in HIV-infected 
patients,62,63 in patients diagnosed with a kidney disease,64–67 
and for patients following myocardial infarction,68,69 or a 
stroke.70 The other measures available in the relative survival 
setting (CNS, RMNST, CPD and NLYL) have received 
much less attention. However, one should be careful when 
using the excess mortality hazard method in a given clini-
cal area, as one key assumption is the availability of a good 
approximation (with life tables) of the mortality hazard due 
to other causes. Depending on the context/geographical area, 
the life table may not provide a reasonable approximation of 
the mortality from other causes; for example, the life table 
in some sub-Saharan countries is hugely impacted by HIV 
mortality. Thus, the excess mortality hazard approach would 
need to account for this, if one is interested in estimating the 
excess mortality due to HIV infection.71
We used observational data to illustrate the depriva-
tion disparities in survival using different measures, and 
these measures were used as exploratory/descriptive tools 
rather than explanatory tools. Indeed, evaluating the effect 
of deprivation on these colon cancer disparities would call 
for methods besides standardization via life table data to 
account for confounding. Recent literature employs some 
of these alternative measures coupled with causal inference 
techniques. For instance, causal inference methods using the 
RMST in the overall survival setting have been developed 
recently.72,73 There are also causal inference studies in the 
context of the competing risks setting with known cause of 
death.74 The restricted mean residual lifetime has also been 
combined with g-computation to estimate an average causal 
effect.75
We presented and described the use of different ways for 
summarizing cancer survival data, each of them contribut-
ing differently to provide information to patients, clinicians, 
health policy makers and health economists on the disease 
disparities in deprivation groups. Even though we illustrated 
the use of these measures using nonparametric estimators, 
parametric and semiparametric hazard-based regression 
models could be also used. We provided the R code for imple-
menting all these measures with the hope that the reader will 
start applying and comparing different and complementary 
measures in the presentation of survival data.
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